{
  "trial_id": "NCT04120974",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, type of diabetes (Type 1 or Type 2), duration of diabetes, HbA1c level at baseline, BMI, presence of lipohypertrophy, daily insulin dose, frequency of hypoglycemic events, quality of life score, internet access, outpatient status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Baseline HbA1c (%)",
          "HbA1c level at baseline"
        ],
        [
          "Diabetes Type: Type I",
          "type of diabetes (Type 1 or Type 2)"
        ],
        [
          "Baseline Lipohypertrophy: Yes",
          "presence of lipohypertrophy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "Insulin therapy duration",
        "average",
        "average (years)",
        "Baseline Lipohypertrophy: No"
      ],
      "remaining_candidate_features": [
        "duration of diabetes",
        "daily insulin dose",
        "frequency of hypoglycemic events",
        "quality of life score",
        "internet access",
        "outpatient status."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Body Mass Index, Duration of Diabetes, Type of Diabetes (Type 1 or Type 2), Baseline HbA1c, Insulin Total Daily Dose (TDD), Presence of Lipohypertrophy, Frequency of Hypoglycemic Events, Quality of Life (QoL) Scores,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "BMI",
          "Body Mass Index"
        ],
        [
          "Baseline HbA1c (%)",
          "Baseline HbA1c"
        ],
        [
          "Diabetes Type: Type I",
          "Type of Diabetes (Type 1 or Type 2)"
        ],
        [
          "Diabetes Type: Type II",
          "Type of Diabetes (Type 1 or Type 2)"
        ],
        [
          "Baseline Lipohypertrophy: Yes",
          "Presence of Lipohypertrophy"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "average",
        "Insulin therapy duration",
        "average (years)",
        "Baseline Lipohypertrophy: No"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Duration of Diabetes",
        "Insulin Total Daily Dose (TDD)",
        "Frequency of Hypoglycemic Events",
        "Quality of Life (QoL) Scores"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "##Answer:\nAge, Continuous, Sex: Female, Male, Diabetes Type, BMI, HbA1c, Insulin Total Daily Dose, Lipohypertrophy Status, Duration of Diabetes, Quality of Life Score,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Baseline HbA1c (%)",
          "HbA1c"
        ],
        [
          "Diabetes Type: Type I",
          "Diabetes Type"
        ],
        [
          "Baseline Lipohypertrophy: Yes",
          "Lipohypertrophy Status"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "average",
        "Type II",
        "Insulin therapy duration",
        "average (years)",
        "Baseline Lipohypertrophy: No"
      ],
      "remaining_candidate_features": [
        "Insulin Total Daily Dose",
        "Duration of Diabetes",
        "Quality of Life Score"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, BMI, diabetes type (Type 1 or Type 2), duration of diabetes, duration of insulin therapy, HbA1c at baseline, insulin Total Daily Dose (TDD) at baseline, presence of lipohypertrophy, quality of life (QoL) at baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Baseline HbA1c (%)",
          "HbA1c at baseline"
        ],
        [
          "Diabetes Type: Type I",
          "diabetes type (Type 1 or Type 2)"
        ],
        [
          "Insulin therapy duration",
          "duration of insulin therapy"
        ],
        [
          "Baseline Lipohypertrophy: Yes",
          "presence of lipohypertrophy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Region of Enrollment",
        "average",
        "Type II",
        "average (years)",
        "Baseline Lipohypertrophy: No"
      ],
      "remaining_candidate_features": [
        "duration of diabetes",
        "insulin Total Daily Dose (TDD) at baseline",
        "quality of life (QoL) at baseline."
      ]
    }
  }
}